Frontier pharma rheumatoid arthritis cytokine mediators and kinase inhibitors dominate first

Frontier Pharma: Rheumatoid Arthritis Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

“The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.�

Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium - the soft tissue of the joint - leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for firstin-class innovation, which is the area most likely to produce substantial clinical advances.

Read Complete Report With TOC @ http://www.radiantinsights.com/research/frontierpharma-rheumatoid-arthritis

Follow Us:

Scope Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.

- What is the pathophysiology of RA? - Which products and therapeutic strategies dominate the clinical and commercial landscapes?

- What are the most significant unmet needs within the RA market?

Considerable diversification from current market trends is evident within the RA pipeline.

- Which molecular targets are most prominent within the pipeline?

- What proportion of pipeline products are first in class?

- Which first-in-class targets are most promising?

Deal values for licensing and co-development deals vary considerably.

- How many strategic consolidations have been completed in the past decade?

- Which types of assets attract the largest deal values?

- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Related reports by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare Reasons to buy This report will allow you to - Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.

- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.

- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-inclass targets in the RA pipeline have been assessed and ranked according to clinical potential.

Promising early-stage targets have been further reviewed in greater detail.

Follow Us:

- Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents 1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3

2 Executive Summary 5 2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining 5 2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation 5 2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products 5 Download sample Copy of This Report at: http://www.radiantinsights.com/research/frontier-pharma-rheumatoidarthritis/request-sample 3 The Case for Innovation 6 3.1 Growing Opportunities for Biologic Products 7 3.2 Diversification of Molecular Targets 7 3.3 Innovative First-in-Class Development Remains Attractive 8 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8 3.5 Sustained Innovation 8 3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10 4.1 Disease Overview 10 4.2 Disease Symptoms 10

Follow Us:

4.3 Epidemiology 11 4.4 Etiology 11 4.5 Pathophysiology 11 4.6 Co-morbidities and Complications 12 4.7 Diagnosis 12 4.7.1 Blood Tests 12 4.7.2 1987 Rheumatoid Arthritis Classification 13 4.7.3 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 13 4.8 Disease Progression 13 4.9 Treatment Options and Treatment Algorithm 14 4.10 Overview of Marketed Products in Rheumatoid Arthritis 15 4.10.1 Molecule Type and Molecular Target Analysis 15 Read Complete Report With TOC @ http://www.radiantinsights.com/research/frontierpharma-rheumatoid-arthritis 5 Assessment of Pipeline Product Innovation 17 5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target 17 5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family 21 5.3 First-in-Class Programs Targeting Novel Molecular Targets 21

6 Signaling Network, Disease Causation and Innovation Alignment 32 6.1 Complexity of Signaling Networks in Rheumatoid Arthritis 32 6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 33 6.3 First-in-Class Matrix Assessment 33

7 First-in-Class Target Evaluation 37

Follow Us:

7.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40) 37 7.2 Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2 (TYK2) 38 7.3 Pipeline Programs Targeting IL-10 and IL-18 39 7.4 Pipeline Programs Targeting 72 kDa Type IV Collagenase (MMP2) 41 7.5 Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7) 42 7.6 Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ) 43 7.7 Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5) 44 7.8 Pipeline Programs Targeting C-X-C Motif Chemokine 10 (CXCL10) and C-X-C Motif Chemokine 13 (CXCL13) 46

8 Strategic Consolidations 48 8.1 Industry-Wide First-in-Class Deals 48 8.2 Licensing Deals 49 8.3 Co-development Deals 52 8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 56

9 Appendix 59 9.1 References 59 9.2 Abbreviations 63 9.3 Research Methodology 64 9.4 Secondary Research 64 9.4.1 Market Analysis 64 9.4.2 Pipeline Analysis 65 9.4.3 First-in-Class Matrix Assessment 65 9.4.4 First-in-Class Target Profiles 65

Follow Us:

About Radiant Insights, Inc: Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036, San Francisco, CA 94105, United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Web: http://www.radiantinsights.com/ Visit Our Blog: http://www.radiantinsightsinc.blogspot.com

Follow Us: